Dr. Reddy’s Laboratories Announces the Re-Launch of Its Buprenorphine and Naloxone Sublingual Film after Favorable Ruling in Patent Litigation

Dr. Reddys Laboratories Ltd. ((BSE: 500124) (NSE: DRREDDY) (NYSE: RDY) along with its subsidiaries together referred to as Dr. Reddys) announced today the re-launch of its Buprenorphine and Naloxone Sublingual Film, 2 mg/0.5 mg, 4 mg/1 mg, 8 mg/2 mg, and 12 mg/3 mg, a therapeutic equivalent generic version of Suboxone (buprenorphine and naloxone) sublingual film, in the United States market.

The re-launch comes on the heels of a favorable decision issued by the United States Court of Appeals for the Federal Circuit concluding that Indivior had not shown that it is likely to succeed on its claim that Dr. Reddys product infringes U.S. Patent No. 9,931,305. The Federal Circuits decision vacates the District Courts preliminary injunction that had prohibited Dr. Reddys from selling its generic version of Suboxone (buprenorphine and naloxone) sublingual film. The Federal Circuits decision went into effect yesterday. As a result of the Federal Circuits ruling, Dr. Reddys has resumed shipping of the product.

We are pleased with the decision of the appellate court in Dr. Reddys favor, vacating the preliminary injunction that had prevented Dr. Reddys from continuing to market this important drug to the public, explains Marc Kikuchi, Chief Executive Officer, North America Generics. Dr. Reddys is committed to providing affordable treatment options for opioid use disorder and addiction. We look forward to helping patients and our communities in the United States who are impacted by the opioid epidemic.

In June 2018, the U.S. Food and Drug Administration (USFDA) approved Dr. Reddys Buprenorphine and Naloxone Sublingual Film, in four strengths including 2 mg/0.5 mg, 4 mg/1 mg, 8 mg/2 mg, and 12 mg/3 mg, for sale in the U.S. market. The product was launched immediately after approval, with sales and commercialization activities halted as a result of a court-imposed temporary restraining order (TRO) and preliminary injunction against Dr. Reddys. The TRO and preliminary injunction did not prohibit commercial manufacturing of the product.

Please click below for full Prescribing Information including Medication Guide.

WANT TO BUILD A FINANCIAL EMPIRE?

Subscribe to the Global Banking & Finance Review Newsletter for FREE
Get Access to Exclusive Reports to Save Time & Money

By using this form you agree with the storage and handling of your data by this website. We Will Not Spam, Rent, or Sell Your Information.
All emails include an unsubscribe link. You may opt-out at any time. See our privacy policy.

http://www.drreddys.com/pi/Buprenorphine_and_Naloxone_Sublingual_Film_2mg-0.5mg_and_8mg-2mg_Prescribing_Information.pdf

http://www.drreddys.com/pi/Buprenorphine_and_Naloxone_Sublingual_Film_4mg-1mg_and_12mg-3mg_Prescribing_Information.pdf

Suboxone is a registered trademark of Indivior UK Ltd.

RDY-0219-238

About Dr. Reddys: Dr. Reddys Laboratories Ltd. (BSE: 500124) (NSE: DRREDDY) (NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses – Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products “ Dr. Reddys offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddys operates in markets across the globe. Our major markets include “ USA, India, Russia & CIS countries, and Europe. For more information, log on to: www.drreddys.com.

Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the managements current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words “may,” “will,” “should,” “expects,” “plans,” “intends,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” or “continue” and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults, currency exchange rates, interest rates, persistency levels and frequency / severity of insured loss events, (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization, including related integration issues.

The company assumes no obligation to update any information contained herein.

INVESTOR RELATIONS
AMIT AGARWAL
[email protected]
(Ph:
+91-40-49002135)

MEDIA RELATIONS
MITALI SARKAR
[email protected]
(Ph:
+91-40-49002121)